Pregabalin for neuropathic pain based on recent clinical trials.
Pregabalin is a ligand for the alpha-2-delta subunit of voltage-gated calcium channels with anticonvulsant, analgesic, and anxiolytic properties. It has predictable absorption across the gastrointestinal tract, is neither metabolized nor protein-bound, and has minimal drug-drug interactions. It is effective with two or three-times daily dosing in a dose range of 150 to 600 mg daily. Seven published prospective, randomized clinical trials in postherpetic neuralgia (PHN) and painful diabetic peripheral neuropathy (DPN) demonstrate pain relief, decreased sleep interference, and improvements in several secondary outcome measures. The 50% responder rates for PHN and DPN compare favorably with other first-line agents for neuropathic pain. Pregabalin is well tolerated in most patients with infrequent severe adverse effects. Pregabalin is an important addition to the treatment armamentarium for neuropathic pain.
Stacey
Brett R
BR
Department of Anesthesiology & Peri-Operative Medicine, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Mailcode OP-26, Portland, OR 97239, USA. staceyb@ohsu.edu
Swift
Jon N
JN
D000700:Analgesics / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D009437:Neuralgia / Q000188:drug therapy*; D000069583:Pregabalin; D016896:Treatment Outcome; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
D000700:Analgesics; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid
J Clin Psychopharmacol. 2004 Apr;24(2):141-9
15206660
Ann Neurol. 2005 Aug;58(2):309-12
15991228
Arch Gen Psychiatry. 2005 Sep;62(9):1022-30
16143734
Med Lett Drugs Ther. 2005 Sep 12;47(1217):75-6, 73
16151369
Epilepsy Res. 1998 Jul;31(2):91-9
9714500
Neurobiol Dis. 1998 Oct;5(4):209-27
9848092
PLoS Med. 2005 Jul;2(7):e164
16013891
J Clin Psychopharmacol. 2003 Jun;23(3):240-9
12826986
Epilepsy Res. 2000 Jul;40(2-3):123-7
10863139
Drugs. 2005;65(1):111-8; discussion 119-20
15610058
Curr Opin Pharmacol. 2006 Feb;6(1):108-13
16376147
J Pain Symptom Manage. 2005 Oct;30(4):374-85
16256902
Pain. 2005 Dec 5;118(3):289-305
16213659
Pain. 2005 Jun;115(3):254-263
15911152
Drugs. 2004;64(24):2813-20; discussion 2821
15563250
Am J Psychiatry. 2003 Mar;160(3):533-40
12611835
J Clin Endocrinol Metab. 2005 Aug;90(8):4936-45
15899953
Pain. 2004 May;109(1-2):26-35
15082123
Neurology. 2003 Apr 22;60(8):1274-83
12707429
Reg Anesth Pain Med. 1999 Jan-Feb;24(1):5-7
9952087
Acta Neurol Scand. 2004 Dec;110(6):368-76
15527449
J Pain. 2005 Apr;6(4):253-60
15820913
Curr Med Res Opin. 2006 Feb;22(2):375-84
16466610
Neurology. 2004 Sep 28;63(6):959-65
15452284
Evid Based Ment Health. 2004 Feb;7(1):17
14769661
Ann Pharmacother. 2005 Dec;39(12):2029-37
16288079
Pain. 2005 Mar;114(1-2):29-36
15733628
Clin J Pain. 2006 Jan;22(1 Suppl):S2-8
16344609
Am J Phys Med Rehabil. 2005 Mar;84(3 Suppl):S4-16
15722782
J Pharmacol Exp Ther. 2005 Jun;313(3):1406-15
15769862
Pharm Res. 2001 Aug;18(8):1126-30
11587483
Epilepsia. 2004;45 Suppl 6:13-8
15315511
Prescrire Int. 2005 Dec;14(80):203-6
16397976
Pain. 2001 Nov;94(2):149-158
11690728
Epilepsia. 2005 Sep;46(9):1407-13
16146435
Sleep. 2005 Feb;28(2):187-93
16171242
Arthritis Rheum. 2005 Apr;52(4):1264-73
15818684
Pain. 2004 Aug;110(3):628-638
15288403
J Clin Psychopharmacol. 2005 Apr;25(2):151-8
15738746
Fed Regist. 2005 Jul 28;70(144):43633-5
16050051
Neurology. 2004 Dec 14;63(11):2104-10
15596757
Neurology. 2005 Dec 29;65(12 Suppl 4):S66-73
16385106